SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (a foreign private issuer), not Lakefront Biotherapeutics NV, for the month of November 2025. The filing, dated November 6, 2025, serves to incorporate by reference a press release issued on November 5, 2025 (Exhibit 99.1). The registrant is headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
No material financial changes or comparative period data are presented in the text of this Form 6-K. The document references a press release for substantive updates but does not summarize those details.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not explicitly state guidance, outlook, management commentary, risks, or contingencies in the body text provided. The text notes that quotes from Henry Gosebruch and Aaron Cox in the press release are excluded from incorporation by reference into certain registration statements.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Galapagos NV, not Lakefront Biotherapeutics NV.
- Review Exhibit 99.1 (Press Release dated November 5, 2025) for the actual content of the announcement.
- Confirm that no financial metrics are available in this specific filing text.
- Note that specific quotes from Henry Gosebruch and Aaron Cox are excluded from incorporation into Form S-8 registration statements.